(Q37764347)

22 August 2017

title

Memantine ER, a once-daily formulation for the treatment of Alzheimer's disease (English)

1 reference

22 August 2017

0 references

Nazem Bassil

1

1 reference

22 August 2017

Papan Thaipisuttikul

series ordinal

2

1 reference

22 August 2017

George T Grossberg

series ordinal

3

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 July 2010

1 reference

Expert Opinion on Pharmacotherapy

22 August 2017

published in

1 reference

22 August 2017

volume

11

1 reference

22 August 2017

issue

10

1 reference

22 August 2017

page(s)

1765-1771

1 reference

Alzheimer disease: current concepts and emerging diagnostic and therapeutic strategies

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.493874

Alzheimer's disease and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.493874

Prevalence of AD among whites: a summary by levels of severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.493874

Global prevalence of dementia: a Delphi consensus study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.493874

Effects of memantine and donepezil on amyloid beta-induced memory impairment in a delayed-matching to position task in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.493874

Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.493874

Glutamate and the glutamate receptor system: a target for drug action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.493874

Galantamine: a review of its use in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.493874

The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.493874

Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.493874

A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.493874

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.493874

Memantine in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.493874

Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.493874

The ability of persons with Alzheimer disease (AD) to make a decision about taking an AD treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.493874

Depressive disorders in caregivers of dementia patients: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.493874

Caregiver burden in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.493874

Rationale for transdermal drug administration in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.493874

Novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.493874

Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.493874

Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.493874

Memantine pharmacotherapy: a naturalistic study using a population pharmacokinetic approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.493874

Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.493874

Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.493874

Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.493874

Memantine for the treatment of Alzheimer's disease: tolerability and safety data from clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.493874

Update on the use of memantine in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.493874

10.1517/14656566.2010.493874

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference